FDAsafety guidance54% confidence
Novel Drug Approvals for 2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (her2) as Enhertu recommended for EU approval in HER2+ metastatic solid tumours.
Regulatory Analysis
Novel Drug Approvals for 2026
Supporting Context
- Therapeutic area
- Oncology · HER2-positive solid tumours
- Sub-indication
- HER2
Related signal: Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Source
FDA document
View source